ACTA1 and COVID-19: Overall, the low nanomolar concentration of niclosamide required to decrease ECM deposition and αSMA expression (Figs. 3Band4A) combined with relatively low toxicity and apoptosis induction at concentrations <100 nM (Fig. 4B–D) makes a strong case for further investigation in all stages of COVID-19.